Inflammatory Disease News and Research

RSS

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Three new loci linked to asthma susceptibility in Japanese population

Researchers at the RIKEN Center for Genomic Medicine (CGM), together with colleagues at Kyoto University, Tsukuba University, Harvard University, and other medical institutions have identified three new loci associated with susceptibility to adult asthma in the Japanese population.

1 Aug 2011

New details about how dendritic cells regulate fate of naive T cells

St. Jude Children's Research Hospital scientists show that the molecule serves as a bridge between the two arms of the immune system that provides a new mechanism guiding T cell differentiation.

25 Jul 2011

Partners of Bacterial Vaginosis sufferers at increased risk of HIV

Starpharma Holdings Limited today commented on results of a study which showed that men were three times more likely to contract HIV from their female partners if the women also had bacterial vaginosis (BV) in the three months before the men became infected.

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

Sexually transmitted diseases more common in women age 40

A Johns Hopkins infectious disease expert is calling for all sexually active American women age 40 and older to get tested for the parasite Trichomonas vaginalis after new study evidence found that the sexually transmitted disease (STD) is more than twice as common in this age group than previously thought.

12 Jul 2011

Solution for treating obesity-related diseases may reside in fat tissue

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have shown that the quality – not just the quantity – of adipose, or fat, tissue is a significant contributing factor in the development of inflammation and vascular disease in obese individuals. The study, which is a special feature on the iPAD version of the Journal of the American College of Cardiology, provides compelling evidence that the answer to treating cardiovascular disease and other obesity-related disorders, such as type 2 diabetes and cancer, might be found in the adipose tissue itself.

7 Jul 2011

Periodontal disease can affect woman's chance of conceiving

Professor Roger Hart told the annual meeting of the European Society of Human Reproduction and Embryology that the negative effect of gum disease on conception was of the same order of magnitude as the effect of obesity.

5 Jul 2011

Incidence of osteoarthritis more prevalent among military populations

New research shows significantly higher osteoarthritis (OA) incidence rates in military populations than among comparable age groups in the general population.

30 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

In a study that included nearly 14,000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011

Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder

Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6).

20 Jun 2011

Research reveals how humans of different ancestry process polyunsaturated fat

Over the past decade, much progress has been made regarding the understanding and promise of personalized medicine. Scientists are just beginning to consider the impact of gene-diet interactions in different populations in regards to disease prevention and treatment.

15 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.

10 Jun 2011

Study explores link between hospital procedure volume, surgical outcomes after joint replacements

Patients who undergo elective total hip or total knee arthroplasty at hospitals with lower surgical volume had a higher risk of venous thromboembolism and mortality following the procedure.

7 Jun 2011

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Emergent BioSolutions Inc. announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

6 Jun 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011